10 November 2020
Melbourne, Australia – A new study by Monash University has found that obstructive sleep apnea (OSA) has been linked to an increased risk of dementia. The study, published in the Journal of Alzheimer’s Disease, and led by Dr. Melinda Jackson from the Turner Institute for Brain and Mental Health, found that severe OSA is linked to an increase in a protein, called beta-amyloid, that builds up on the walls of the arteries in the brain and increases the risk of dementia.
The study involved 34 individuals with recently diagnosed untreated OSA and 12 individuals who were asymptomatic for sleep disorders. It explored associations between brain amyloid burden using a PET brain scan, and measures of sleep, demographics and mood.
The OSA group recorded a higher amyloid burden, poorer sleep efficiency and less time spent in stage N3 sleep (a regenerative period where your body heals and repairs itself).
OSA is a common sleep disorder, affecting about 1 billion people worldwide and is caused by the collapse of the airway during sleep, resulting in intermittent dips in oxygen levels and arousals from sleep.
“The significance of finding the association between increased brain amyloid in patients with OSA will allow for further research to explore in more detail the implications of treating OSA for reducing dementia risk,” Dr. Jackson said.
NOTES FOR EDITORS
Full study: "Severe Obstructive Sleep Apnea Is Associated with Higher Brain Amyloid Burden: A Preliminary PET Imaging Study" by ML Jackson, M Cavuoto, R Schembri, V Doré, VL Villemagne, M Barnes, FJ O’Donoghue, CC Rowe, and SR Robinson (DOI: 10.3233/JAD-200571) published in the Journal of Alzheimer’s Disease, Volume 78, Issue 2 by IOS Press. The article is available online at: content.iospress.com/articles/journal-of-alzheimers-disease/jad200571.
Media office of Monash University (firstname.lastname@example.org or +61 425 725 836).
About the Journal of Alzheimer’s Disease
Now in its 23rd year of publication, the Journal of Alzheimer's Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 3.909 according to Journal Citation Reports (Source: Clarivate, 2020). It is published by IOS Press. j-alz.com